Clinical evidence on RefluG™ ISOREPAIR: new brochure available

8 June 2021

Giellepi is glad to announce the new brochure with the latest clinical evidence on RefluG™ Isorepair, the new barrier therapy for gastroesophageal reflux.

Download the brochure and find out more about the latest clinical evidence on RefluG™ Isorepair

Download here

RefluG™ Isorepair is an innovative substance-based medical device class IIa designed to reduce gastroesophageal reflux symptoms through a topical protectant and regenerative effect of the esophageal mucosa.

With the double-blind, placebo-controlled, randomized clinical trial (Ribaldone et al., 2020), RefluG™ Isorepair confirms to be safe and efficient in fast symptoms reduction.

RefluG™ Isorepair is a liquid gel indicated for the treatment of common GERD symptoms including heartburn, regurgitation, retrosternal pain, difficulty of swallowing, chronic cough, and acid taste. It provides mucosal protection against acid and pepsin, supporting the physiological reparative mechanism of the gastroesophageal mucosa.

Discover updated clinical data about RefluG Isorepair

Download here

Fill out the form to contact us

We respond to any technical or commercial request:


    Stay updated on news

    * indicates required